See more : Atlantic Energy Solutions, Inc. (AESO) Income Statement Analysis – Financial Results
Complete financial analysis of MaxCyte, Inc. (MXCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MaxCyte, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- China Uptown Group Company Limited (2330.HK) Income Statement Analysis – Financial Results
- Devin Energy Corporation (DVNGF) Income Statement Analysis – Financial Results
- Transgene Biotek Limited (TRABI.BO) Income Statement Analysis – Financial Results
- Digihost Technology Inc. (DGHI) Income Statement Analysis – Financial Results
- Happy Town Holdings Inc. (HPTN) Income Statement Analysis – Financial Results
MaxCyte, Inc. (MXCT)
About MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 41.29M | 44.26M | 33.89M | 26.17M | 21.62M | 16.67M | 13.99M | 12.27M | 9.29M | 7.16M | 6.81M | 5.06M |
Cost of Revenue | 4.74M | 5.10M | 3.65M | 2.77M | 2.50M | 1.84M | 1.45M | 1.31M | 1.03M | 957.50K | 808.60K | 830.40K |
Gross Profit | 36.55M | 39.16M | 30.25M | 23.40M | 19.12M | 14.83M | 12.53M | 10.96M | 8.26M | 6.21M | 6.00M | 4.23M |
Gross Profit Ratio | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% | 88.96% | 89.61% | 89.34% | 88.89% | 86.64% | 88.12% | 83.59% |
Research & Development | 23.82M | 19.51M | 15.41M | 17.74M | 17.60M | 11.24M | 11.28M | 4.70M | 3.01M | 2.49M | 2.22M | 2.21M |
General & Administrative | 30.07M | 25.83M | 18.68M | 8.39M | 6.09M | 5.28M | 4.52M | 4.20M | 2.67M | 2.47M | 2.21M | 2.02M |
Selling & Marketing | 26.98M | 18.65M | 13.00M | 8.33M | 7.85M | 6.72M | 6.02M | 4.78M | 3.34M | 2.52M | 2.37M | 1.96M |
SG&A | 57.04M | 44.48M | 31.68M | 16.71M | 13.94M | 12.01M | 10.54M | 8.99M | 6.01M | 4.99M | 4.59M | 3.98M |
Other Expenses | 3.99M | 2.53M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 15.70K | 20.00K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 84.85M | 66.52M | 48.44M | 34.46M | 31.54M | 23.25M | 21.82M | 13.69M | 9.02M | 7.48M | 6.80M | 6.19M |
Cost & Expenses | 89.59M | 71.62M | 52.08M | 37.23M | 34.04M | 25.09M | 23.28M | 14.99M | 10.05M | 8.44M | 7.61M | 7.02M |
Interest Income | 10.38M | 3.92M | 150.80K | 65.90K | 206.10K | 170.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.80K |
Interest Expense | 0.00 | 126.90K | 1.04M | 825.60K | 681.10K | 614.60K | 625.30K | 637.80K | 704.40K | 561.30K | 153.50K | 61.70K |
Depreciation & Amortization | 4.17M | 2.70M | 1.42M | 1.05M | 613.50K | 344.00K | 142.90K | 105.70K | 93.30K | 92.00K | 116.40K | 115.20K |
EBITDA | -44.13M | -20.87M | -16.76M | -9.94M | -11.60M | -7.91M | -9.15M | -2.60M | -647.80K | -1.18M | -688.30K | -1.81M |
EBITDA Ratio | -106.88% | -46.87% | -49.02% | -38.00% | -53.65% | -47.46% | -65.42% | -21.21% | -6.97% | -16.52% | -10.11% | -35.80% |
Operating Income | -48.30M | -27.36M | -18.19M | -11.06M | -12.42M | -8.42M | -9.29M | -2.72M | -761.10K | -1.28M | -804.70K | -1.96M |
Operating Income Ratio | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% | -50.55% | -66.44% | -22.20% | -8.19% | -17.81% | -11.83% | -38.79% |
Total Other Income/Expenses | 10.38M | 3.79M | -893.60K | -759.70K | -475.00K | -444.30K | -625.30K | -622.10K | -684.40K | -561.30K | -153.50K | -25.90K |
Income Before Tax | -37.92M | -23.57M | -19.08M | -11.82M | -12.90M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
Income Before Tax Ratio | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
Income Tax Expense | 0.00 | -3.79M | 1.04M | 825.60K | 681.10K | 170.30K | 0.00 | 653.50K | 724.40K | 0.00 | 0.00 | 35.80K |
Net Income | -37.92M | -19.78M | -20.13M | -12.64M | -13.58M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
Net Income Ratio | -91.85% | -44.69% | -59.38% | -48.31% | -62.79% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
EPS | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
EPS Diluted | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
Weighted Avg Shares Out | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
Weighted Avg Shares Out (Dil) | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
Why Is MaxCyte (MXCT) Stock Down 21% Today?
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
MaxCyte to Participate in Baird Global Healthcare Conference
MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
Source: https://incomestatements.info
Category: Stock Reports